A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry.
We’re maintaining the criteria we used for last year’s tracker, which means including financing rounds north of $50 million. Of course, we’ll still profile innovative new companies and larger rounds in-depth, while we focus more coverage on clinical trial results, M&A and special reports.
Related
January
Jan. 6—Orbis Medicines
Series: A
Amount: €90 million (About $93.4 million)
Investors: NEA (New Enterprise Associates), Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion.
Danish biotech Orbis has closed its first series financing, money that will be used for oral macrocycle drug discovery. The biotech has also tapped Morten Graugaard to lead as CEO after three years of serving as executive chair of Orbis’ board of directors. Graugaard is a Novo Holdings partner with more than 20 years of experience in the life sciences. Under his leadership, the biotech will work to develop oral macrocycles—a drug class that has historically been difficult to create oral versions of—as alternatives to blockbuster drugs. Release
